<DOC>
	<DOCNO>NCT00594581</DOCNO>
	<brief_summary>This study undertaken investigate safety scar-improvement activity different application Juvista ( avotermin ) , administer surgical incision make skin healthy population male volunteer age 18-45 year . The study address two issue : whether Juvista ( avotermin ) administer 200ng/100μl/linear cm wound margin effective 50ng/100μl/linear cm scar improvement , secondly , whether dose ( wound ) twice ( wound ) optimal scar improvement .</brief_summary>
	<brief_title>Anti-Scarring Efficacy Safety Intradermal Juvista ( Avotermin ) Healthy Males</brief_title>
	<detailed_description />
	<mesh_term>Cicatrix</mesh_term>
	<criteria>Clinically healthy , male subject age 18 45 year ( inclusive ) Body weight 40kg 150kg body mass index within range 1555kg/m2 , calculate use Quetelet 's index Subjects history evidence hypertrophic keloid scarring , tattoo previous scar area biopsied . Subjects tattoo previous scar within 3cm area incise trial . AfroCaribbean volunteer , increase susceptibility hypertrophic keloid scarring . Subjects , direct question physical examination , evidence past present clinically significant disease . Subjects chronic currently active skin disorder , would adversely affect heal acute wound involve area examine trial . Subjects history clinically significant allergy . Subjects clinically significant abnormality follow review pretrial laboratory data physical examination . Subjects take , take , certain prescribe drug 4 week Day 0 , particular , topical systemic steroid , antiinflammatory , anticoagulant , antiproliferative drug , antibiotic . Subjects take part clinical trial within 3 month admission trial , currently participate clinical trial , whether investigational drug involve . Subjects clinical evidence severe ongoing , prolong , depression mental illness . Subjects smoke 20 cigarette day . Subjects drink 28 unit alcohol per week ( 1 unit = ½ pint beer [ 285ml ] , 25ml spirit , 1 glass wine ) . Subjects show evidence drug abuse . Subjects know , , serum hepatitis carrier hepatitis B surface antigen ( HbsAg ) hepatitis C antibody . Subjects previously test positive HIV antibody , admit belong highrisk group . Subjects preexist clinically significant neurological condition . Subjects , opinion investigator , likely complete trial whatever reason .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>cicatrix , scar , TGF-beta3 , avotermin , Juvista</keyword>
</DOC>